Claims

1. An antibody or binding fragment specific to the FBG domain of tenascin C, comprising:

   a VH region wherein CDRH1 is SEQ ID NO: 9, CDRH2 is SEQ ID NO: 10, and CDRH3 is independently selected from SEQ ID NO: 11, 30, 32, 34, 36, 38, 40, 42, 44 and 46, and

   a VL region wherein a CDRL1 is SEQ ID NO: 5, CDRL2 is SEQ ID NO: 13 and CDRL3 is SEQ ID NO: 14.

2. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 11.

3. The antibody or binding fragment according to claim 2, wherein the VH region has a sequence shown in SEQ ID NO: 12.

4. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 30.

5. The antibody or binding fragment according to claim 4, wherein the VH region has a sequence shown in SEQ ID NO: 31.

6. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 34.

7. The antibody or binding fragment according to claim 6, wherein the VH region has a sequence shown in SEQ ID NO: 35.

8. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 36.

9. The antibody or binding fragment according to claim 8, wherein the VH region has a sequence shown in SEQ ID NO: 37.

10. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 38.

11. The antibody or binding fragment according to claim 10, wherein the VH region has a sequence shown in SEQ ID NO: 39.

12. The antibody or binding fragment according to claim 1, wherein CDRH3 is SEQ ID NO: 42.

13. The antibody or binding fragment according to claim 16, wherein the VH region has a sequence shown in SEQ ID NO: 43.

14. The antibody or binding fragment according to any one of claims 1 to 13, wherein the VL region has a sequence shown in SEQ ID NO: 15.

15. The antibody or binding fragment according to any one of claims 1 to 14, wherein the antibody or binding fragment is humanised or fully human.

16. A composition comprising an antibody or binding fragment according to any one claims 1 to 15 and a pharmaceutically acceptable carrier, excipient and/or diluent.

17. The composition according to claim 16, wherein composition further comprises an agent selected from the group consisting of: an anti-inflammatory agent, such as non-steroidal anti-inflammatories (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs); a statin; a biological agent; an immunosuppressive agent, a salicylate and a microbicidal agent.

18. Use of an antibody or binding fragment according to any one of claims 1 to 15 or a composition according to claims 16 or 17 in the manufacture of a medicament for use in the treatment of a chronic inflammatory condition, wherein the chronic inflammatory condition is rheumatoid arthritis (RA).